Mark Shearman

Mark Shearman

Algemeen Directeur bij
Aprinoia Therapeutics, Inc. /US/
64 jaar
Health Technology
Consumer Services

Profiel

Mark S.
Shearman
is currently the Chief Executive Officer & Director at Aprinoia Therapeutics, Inc. He previously held positions as the Executive Director-Neuroscience at Merck & Co., Inc., the Executive Director at Merck Research Laboratories Massachusetts LLC, and the Senior Director-Cellular & Molecular Neuroscience at Merck Sharp & Dohme Research Laboratories Neuroscience Research.
He also served as the Senior VP-Research & Early Development at Merck KGaA and the Chief Scientific Officer & Vice President at Beacon Therapeutics (USA), Inc. Dr. Shearman's most recent former position was as the Chief Scientific Officer & Executive VP at Editas Medicine, Inc. He received his undergraduate degree from the University of Bristol and his doctorate from The University of Nottingham.

Actieve functies van Mark Shearman

BedrijvenFunctieBegin
Algemeen Directeur 14-07-2023

Eerdere bekende functies van Mark Shearman

BedrijvenFunctieEinde
APPLIED GENETIC TECHNOLOGIES CORPORATION Hoofd Techniek/Wetenschap/O&O 20-04-2021
MERCK KGAA Corporate Officer/Principal 01-01-2015
Directeur/Bestuurslid 01-07-2009
MERCK & CO., INC. Corporate Officer/Principal 01-01-2009
Merck Sharp & Dohme Research Laboratories Neuroscience Researc
Corporate Officer/Principal 01-01-2005
Ervaring van Mark Shearman in detail bekijken

Opleiding van Mark Shearman

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Connecties

86

Eerstegraads connecties

10

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Verwante bedrijven

Bedrijven in privébezit10

Health Technology

Health Technology

Consumer Services

Health Technology

Consumer Services

Health Technology

Health Technology

Health Technology

Merck Sharp & Dohme Research Laboratories Neuroscience Researc

Health Technology

  1. Beurs
  2. Insiders
  3. Mark Shearman
40 % korting: de beste tools voorbehouden aan abonnees om de beste beleggingen van morgen te identificeren!
d
:
:
PROFITEER NU